Antibiotice Iasi has commissioned a 2.5 MW photovoltaic plant, financed by the RRRP, which will provide over 25% of the electricity requirements
- the 2.5 MW ground photovoltaic plant will provide 26.4% of the company’s electricity needs
- the new facility will produce an average of 3.500 MWh/year, contributing to the reduction of greenhouse gases by over 2.000 tons per year
- in 2024, an assembly of photovoltaic panels will also be implemented on the company’s buildings with a power of 1.2 MW, so that the green energy production will ensure an energy autonomy up to approximately 35% of the needs of the industrial platform
Photovoltaic plant at Antibiotice Iasi
Antibiotice Iasi commissioned a 2.5 MW photovoltaic power plant, an investment that is part of the company’s sustainable development strategy. The photovoltaic plant project was implemented by Parapet, a construction company operating in the renewable sector, providing design, mechanical, electrical and management infrastructure solutions. The total investment in this project is worth 11.8 million lei, of which the amount of 4.078.620 lei is granted by The Ministry of Energy from European funds related to the Romanian Recovery and Resilience Plan (RRRP) and the remaining amount is provided from the company’s own funds.
The photovoltaic power plant ensures the production of an annual amount of electricity that will cover 26.4% of the operating needs of the industrial platform in the city of Iasi, based on the consumption recorded in 2021. The new facility will produce, on average, 3.500 MWh/year, thus reducing the carbon footprint by more than 2.000 tons annually and will contribute to the development of resilience to climate change by reducing the greenhouse emissions.
“The reduction of the carbon footprint, in the strive of the EU to achieve the climate neutrality by 2050, is a strategic concern for Antibiotice. We have built an energy efficiency strategy on our platform to ensure a certain degree of energy autonomy in industrial processes and this investment is an important step towards this goal. From the total annual energy consumed, we will ensure, through this photovoltaic park, more than a quarter of the energy from renewable sources and this aspect will significantly contribute to the decarbonization process”, stated Mr. Ioan Nani, the General Director of Antibiotice Iasi.
The new electricity production capacity from renewable sources (solar energy) is located on the ground, on the company’s platform and it stretches over a built surface of 31.428 m2, with 4.680 photovoltaic panels installed. The development of the photovoltaic park was carried out in four months, being a real deployment of forces and equipment, being applied one of the principles of sustainability: DNSH (Do No Significant Harm) which requires building sustainably, safely and efficiently in a way that it does not impact the environment, throughout the duration of the project and during all its stages, from the design to the decommissioning stage.
“We are happy to see an increasing number of Romanian companies, from various economic fields, involved in the efficiency of electricity production and consumption, and equally concerned with the sustainable development of their activity. We focus on each one’s needs and we come up with customized, tailored solutions to help them achieve their goal, i.e. to ensure as much of their electricity needs as possible from their own, renewable sources. The photovoltaic plant installed for Antibiotice Iasi is a reference project in this respect and we are happy to be part of the sustainability solutions adopted by the company”, stated Mrs. Andrada Moldovan, the CEO of Parapet.
Also, this year, Antibiotice will implement an assembly of photovoltaic panels on the buildings within the company with a power of 1.2 MW, so that the production of green energy will ensure an autonomy in terms of energy up to approximately 35% of the needs of the industrial platform. Currently, the company’s sustainability strategy focuses on measures to reduce carbon emissions through energy efficiency, by renewing the fleet with electric cars and also by increasing the percentage of electricity purchased from renewable sources.
The investment in electricity production capacities from renewable sources represents a sustainability component of the “The Future Together 2020-2030” Business Plan, by which the Antibiotice shareholders have established ambitious objectives for the sustainable growth of the business for the coming years.
About Antibiotice
Established in 1955, Antibiotice has a tradition of almost 70 years in the manufacture of finished pharmaceutical products and active pharmaceutical ingredients (APIs). Currently, the company is the world leader in the production of Nystatin API and the largest Romanian manufacturer of generic drugs, having solid business partnerships with various international entities. The expansion into global markets has been promoted through substantial investment and a firm commitment to international quality standards such as EU GMP, CoS and US FDA. Its multidisciplinary team of specialists constantly focuses on high performance through various training programs carried out within the Academy a+, in cooperation with relevant universities, as well as through modern motivational and organizational culture systems.
About Parapet
Parapet is a Romanian construction company in the renewable energy and road safety sectors, with headquarters in Cluj-Napoca, Bucharest and Nuremberg. It has a rich portfolio of photovoltaic parks and mixed power plants, photovoltaic – wind – with storage, built “turn-key” powerplants or in different stages, in 15 countries in Europe. The company offers EPC and BoS solutions and services and it owns one of the largest fleets of machinery and equipment in the country, adapted to the two sectors in which it operates. The organizational structure of Parapet includes internal departments dedicated to each stage of construction of a photovoltaic or hybrid park.
